|Trade names||iOSAT, SSKI, ThyroSafe, ThyroShield, others|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|3D model (JSmol)|
|Melting point||681 °C (1,258 °F)|
|Boiling point||1,330 °C (2,430 °F)|
|Solubility in water||1280 mg/mL (0 °C (32 °F)) |
1400 mg/mL (20 °C (68 °F))
1760 mg/mL (60 °C (140 °F))
2060 mg/mL (100 °C (212 °F))
Potassium iodide is a chemical compound, medication, and dietary supplement. It is a medication used for treating hyperthyroidism, in radiation emergencies, and for protecting the thyroid gland when certain types of radiopharmaceuticals are used. In the third world it is also used for treating skin sporotrichosis and phycomycosis. It is a supplement used by people with low dietary intake of iodine. It is administered orally.
Common side effects include vomiting, diarrhea, abdominal pain, rash, and swelling of the salivary glands. Other side effects include allergic reactions, headache, goitre, and depression. While use during pregnancy may harm the baby, its use is still recommended in radiation emergencies. Potassium iodide has the chemical formula KI. Commercially it is made by mixing potassium hydroxide with iodine.
Potassium iodide has been used medically since at least 1820. It is on the World Health Organization's List of Essential Medicines. Potassium iodide is available as a generic medication and over the counter. Potassium iodide is also used for the iodization of salt.
Potassium-iodide is a nutritional-supplement in animal feeds and also in the human diet. In humans it is the most common additive used for "iodizing" table salt (a public health measure to prevent iodine deficiency in populations that get little seafood). The oxidation of iodide causes slow loss of iodine content from iodised salts that are exposed to excess air. The alkali metal iodide salt, over time and exposure to excess oxygen and carbon dioxide, slowly oxidizes to metal carbonate and elemental iodine, which then evaporates. Potassium iodate (KIO3) is used to iodize some salts so that the iodine is not lost by oxidation. Dextrose or sodium thiosulfate are often added to iodized table salt to stabilize potassium iodide thus reducing loss of the volatile chemical.
Thyroid iodine uptake blockade with potassium iodide is used in nuclear medicine scintigraphy and therapy with some radioiodinated compounds that are not targeted to the thyroid, such as iobenguane (MIBG), which is used to image or treat neural tissue tumors, or iodinated fibrinogen, which is used in fibrinogen scans to investigate clotting. These compounds contain iodine, but not in the iodide form. However, since they may be ultimately metabolized or break down to radioactive iodide, it is common to administer non-radioactive potassium iodide to ensure that iodide from these radiopharmaceuticals is not sequestered by the normal affinity of the thyroid for iodide.
U.S. Food and Drug Administration-approved dosing of potassium iodide for this purpose with iobenguane, is as follows (per 24 hours): infants less than 1 month old, 16 mg; children 1 month to 3 years, 32 mg; children 3 years to 18 years, 65 mg; adults 130 mg. However, some sources recommend alternative dosing regimens.
Not all sources are in agreement on the necessary duration of thyroid blockade, although agreement appears to have been reached about the necessity of blockade for both scintigraphic and therapeutic applications of iobenguane. Commercially available iobenguane is labeled with iodine-123, and product labeling recommends administration of potassium iodide 1 hour prior to administration of the radiopharmaceutical for all age groups, while the European Association of Nuclear Medicine recommends (for iobenguane labeled with either isotope), that potassium iodide administration begin one day prior to radiopharmaceutical administration, and continue until the day following the injection, with the exception of new-borns, who do not require potassium iodide doses following radiopharmaceutical injection.
Product labeling for diagnostic iodine-131 iobenguane recommends potassium iodide administration one day before injection and continuing 5 to 7 days following administration, in keeping with the much longer half-life of this isotope and its greater danger to the thyroid. Iodine-131 iobenguane used for therapeutic purposes requires a different pre-medication duration, beginning 24–48 hours prior to iobenguane injection and continuing 10–15 days following injection.
|Age||KI in mg per day|
|Over 12 years old||130|
|3 – 12 years old||65|
|1 – 36 months old||32|
|< 1 month old||16|
In 1982, the U.S. Food and Drug Administration approved potassium iodide to protect thyroid glands from radioactive iodine involving accidents or fission emergencies. In an accidental event or attack on a nuclear power plant, or in nuclear bomb fallout, volatile fission product radionuclides may be released. Of these products, 131
(Iodine-131) is one of the most common and is particularly dangerous to the thyroid gland because it may lead to thyroid cancer. By saturating the body with a source of stable iodide prior to exposure, inhaled or ingested 131
tends to be excreted, which prevents radioiodine uptake by the thyroid. According to one 2000 study "KI administered up to 48 h before 131
exposure can almost completely block thyroid uptake and therefore greatly reduce the thyroid absorbed dose. However, KI administration 96 h or more before 131
exposure has no significant protective effect. In contrast, KI administration after exposure to radioiodine induces a smaller and rapidly decreasing blockade effect." For optimal prevention, KI must be dosed daily until a risk of significant exposure to radioiodine by either inhalation or ingestion no longer exists.
Emergency 130 milligrams potassium iodide doses provide 100 mg iodide (the other 30 mg is the potassium in the compound), which is roughly 700 times larger than the normal nutritional need (see recommended dietary allowance) for iodine, which is 150 micrograms (0.15 mg) of iodine (as iodide) per day for an adult. A typical tablet weighs 160 mg, with 130 mg of potassium iodide and 30 mg of excipients, such as binding agents.
Potassium iodide cannot protect against any other mechanisms of radiation poisoning, nor can it provide any degree of protection against dirty bombs that produce radionuclides other than those of iodine.
The World Health Organization does not recommend KI prophylaxis for adults over 40 years, unless the radiation dose from inhaled radioiodine is expected to threaten thyroid function, because the KI side effects increase with age and may exceed the KI protective effects; "...unless doses to the thyroid from inhalation rise to levels threatening thyroid function, that is of the order of about 5 Gy. Such radiation doses will not occur far away from an accident site."
The U.S. Department of Health and Human Services restated these two years later as "The downward KI (potassium iodide) dose adjustment by age group, based on body size considerations, adheres to the principle of minimum effective dose. The recommended standard (daily) dose of KI for all school-age children is the same (65 mg). However, adolescents approaching adult size (i.e., >70 kg [154 lbs]) should receive the full adult dose (130 mg) for maximal block of thyroid radioiodine uptake. Neonates ideally should receive the lowest dose (16 mg) of KI."
SSKI (i.e., the "saturated solution of KI" rather than tablets) may be used in radioiodine-contamination emergencies (i.e., nuclear accidents) to "block" the thyroid's uptake of radioiodine, at a dose of two drops of SSKI per day for an adult. This is not the same as blocking the thyroid's release of thyroid hormone, for which the adult dose is different (and is actually higher by a factor of 7 or 8), and for which KI anti-radiation pills (not a common medical treatment form of KI) are not usually available in pharmacies, or normally used in hospitals, or by physicians. Although the two forms of potassium iodide are completely interchangeable, normally in practice the SSKI solution, which is the historical medical form of high dose iodine, is generally used for all medical purposes save for radioiodine prophylaxis. For protection of the thyroid against radioiodine (iodine-131) contamination, the convenient standard 130 mg KI pill is used, if available. As noted, the equivalent two drops of SSKI (equaling the dose of one KI pill) may be used for this purpose, if the pills are not available.
There is reason for caution with prescribing the ingestion of high doses of potassium iodide and iodate, because their unnecessary use can cause conditions such as the Jod-Basedow phenomena, trigger and/or worsen hyperthyroidism and hypothyroidism, and then cause temporary or even permanent thyroid conditions. It can also cause sialadenitis (an inflammation of the salivary gland), gastrointestinal disturbances, and rashes. Potassium iodide is also not recommended for people with dermatitis herpetiformis and hypocomplementemic vasculitis – conditions that are linked to a risk of iodine sensitivity.
There have been some reports of potassium iodide treatment causing swelling of the parotid gland (one of the three glands that secrete saliva), due to its stimulatory effects on saliva production.
A saturated solution of KI (SSKI) is typically given orally in adult doses several times a day (5 drops of SSKI assumed to be 1⁄3 mL) for thyroid blockade (to prevent the thyroid from excreting thyroid hormone) and occasionally this dose is also used, when iodide is used as an expectorant (the total dose is about one gram KI per day for an adult). The anti-radioiodine doses used for 131
uptake blockade are lower, and range downward from 100 mg a day for an adult, to less than this for children (see table). All of these doses should be compared with the far lower dose of iodine needed in normal nutrition, which is only 150 μg per day (150 micrograms, not milligrams).
At maximal doses, and sometimes at much lower doses, side effects of iodide used for medical reasons, in doses of 1000 times the normal nutritional need, may include: acne, loss of appetite, or upset stomach (especially during the first several days, as the body adjusts to the medication). More severe side effects that require notification of a physician are: fever, weakness, unusual tiredness, swelling in the neck or throat, mouth sores, skin rash, nausea, vomiting, stomach pains, irregular heartbeat, numbness or tingling of the hands or feet, or a metallic taste in the mouth.
In the event of a radioiodine release the ingestion of prophylaxis potassium iodide, if available, or even iodate, would rightly take precedence over perchlorate administration, and would be the first line of defence in protecting the population from a radioiodine release. However, in the event of a radioiodine release too massive and widespread to be controlled by the limited stock of iodide and iodate prophylaxis drugs, then the addition of perchlorate ions to the water supply, or distribution of perchlorate tablets would serve as a cheap, efficacious, second line of defense against carcinogenic radioiodine bioaccumulation.
The ingestion of goitrogen drugs is, much like potassium iodide also not without its dangers, such as hypothyroidism. In all these cases however, despite the risks, the prophylaxis benefits of intervention with iodide, iodate or perchlorate outweigh the serious cancer risk from radioiodine bioaccumulation in regions where radioiodine has sufficiently contaminated the environment.
Potassium iodide in its raw form is a mild irritant and should be handled with gloves. Chronic overexposure can have adverse effects on the thyroid. Potassium iodide is a possible teratogen.
KI is used with silver nitrate to make silver iodide (AgI), an important chemical in film photography. KI is a component in some disinfectants and hair treatment chemicals. KI is also used as a fluorescence quenching agent in biomedical research, an application that takes advantage of collisional quenching of fluorescent substances by the iodide ion. However, for several fluorophores addition of KI in μM-mM concentrations results in increase of fluorescence intensity, and iodide acts as fluorescence enhancer.
Potassium iodide is a component in the electrolyte of dye sensitised solar cells (DSSC) along with iodine.
Potassium iodide finds its most important applications in organic synthesis mainly in the preparation of aryl iodides in the Sandmeyer reaction, starting from aryl amines. Aryl iodides are in turn used to attach aryl groups to other organics by nucleophilic substitution, with iodide ion as the leaving group.
It is a white salt, which is the most commercially significant iodide compound, with approximately 37,000 tons produced in 1985. It absorbs water less readily than sodium iodide, making it easier to work with.
This reaction is employed in the isolation of iodine from natural sources. Air will oxidize iodide, as evidenced by the observation of a purple extract when aged samples of KI are rinsed with dichloromethane. As formed under acidic conditions, hydriodic acid (HI) is a stronger reducing agent.
Unlike I2, I−3 salts can be highly water-soluble. Through this reaction, iodine is used in redox titrations. Aqueous KI3, "Lugol's solution", is used as a disinfectant and as an etchant for gold surfaces.
Potassium iodide's (KI) value as a radiation protective (thyroid blocking) agent was demonstrated following the Chernobyl nuclear reactor disaster in April, 1986. A saturated solution of potassium iodide (SSKI) was administered to 10.5 million children and 7 million adults in Poland as a preventative measure against accumulation of radioactive 131
in the thyroid gland.
Reports differ concerning whether people in the areas immediately surrounding Chernobyl itself were given the supplement. However the US Nuclear Regulatory Commission (NRC) reported, "thousands of measurements of I-131 (radioactive iodine) activity...suggest that the observed levels were lower than would have been expected had this prophylactic measure not been taken. The use of KI...was credited with permissible iodine content in 97% of the evacuees tested."
With the passage of time, people living in irradiated areas where KI was not available have developed thyroid cancer at epidemic levels, which is why the US Food and Drug Administration (FDA) reported "The data clearly demonstrate the risks of thyroid radiation... KI can be used [to] provide safe and effective protection against thyroid cancer caused by irradiation."
Chernobyl also demonstrated that the need to protect the thyroid from radiation was greater than expected. Within ten years of the accident, it became clear that thyroid damage caused by released radioactive iodine was virtually the only adverse health effect that could be measured. As reported by the NRC, studies after the accident showed that "As of 1996, except for thyroid cancer, there has been no confirmed increase in the rates of other cancers, including leukemia, among the... public, that have been attributed to releases from the accident."
But equally important to the question of KI is the fact that radioactivity releases are not "local" events. Researchers at the World Health Organization accurately located and counted the residents with cancer from Chernobyl and were startled to find that "the increase in incidence [of thyroid cancer] has been documented up to 500 km from the accident site... significant doses from radioactive iodine can occur hundreds of kilometers from the site, beyond emergency planning zones." Consequently, far more people than anticipated were affected by the radiation, which caused the United Nations to report in 2002 that "The number of people with thyroid cancer... has exceeded expectations. Over 11,000 cases have already been reported."
Hiroshima and Nagasaki
The Chernobyl findings were consistent with studies of the effects of previous radioactivity releases. In 1945, several hundreds of thousands of people working and residing in the Japanese cities of Hiroshima and Nagasaki were exposed to high levels of radiation after atomic bombs were detonated over the two cities by the United States. Survivors of the A-bombings, also known as hibakusha, have markedly high rates of thyroid disease; a 2006 study of 4091 hibakusha found nearly half the participants (1833; 44.8%) had an identifiable thyroid disease.
An editorial in The Journal of the American Medical Association regarding thyroid diseases in both hibakusha and those affected by the Chernobyl disaster reports that "[a] straight line adequately describes the relationship between radiation dose and thyroid cancer incidence" and states "it is remarkable that a biological effect from a single brief environmental exposure nearly 60 years in the past is still present and can be detected."
Nuclear weapons testing
The development of thyroid cancer among residents in the North Pacific from radioactive fallout following the United States' nuclear weapons testing in the 1950s (on islands nearly 200 miles downwind of the tests) were instrumental in the 1978 decision by the FDA to issue a request for the availability of KI for thyroid protection in the event of a release from a commercial nuclear power plant or weapons-related nuclear incident. Noting that KI's effectiveness was "virtually complete" and finding that iodine in the form of KI was substantially superior to other forms including iodate (KIO3) in terms of safety, effectiveness, lack of side effects, and speed of onset, the FDA invited manufacturers to submit applications to produce and market KI.
It was reported on March 16, 2011, that potassium iodide tablets were given preventively to U.S. Naval air crew members flying within 70 nautical miles of the Fukushima Daiichi Nuclear Power Plant damaged in the earthquake (8.9/9.0 magnitude) and ensuing tsunami on March 11, 2011. The measures were seen as precautions, and the Pentagon said no U.S. forces have shown signs of radiation poisoning. By March 20, the US Navy instructed personnel coming within 100 miles of the reactor to take the pills.
In the Netherlands, the central storage of iodine-pills is located in Zoetermeer, near The Hague. In 2017, the Dutch government distributed pills to hundreds of thousands of residents who lived within a certain distance of nuclear power plants and met some other criteria.
By 2020, potassium iodide tablets are made available free of charge for all residents in all pharmacies throughout the country.
Three companies (Anbex, Inc., Fleming Co, and Recipharm of Sweden) have met the strict FDA requirements for manufacturing and testing of KI, and they offer products (IOSAT, ThyroShield, and ThyroSafe, respectively) which are available for purchase. In 2012, Fleming Co. sold all its product rights and manufacturing facility to other companies and no longer exists. ThyroShield is currently not in production. The Swedish manufacturing facility for Thyrosafe, a half-strength potassium iodide tablet for thyroid protection from radiation, was mentioned on the secret US 2008 Critical Foreign Dependencies Initiative leaked by Wikileaks in 2010.
Tablets of potassium iodide are supplied for emergency purposes related to blockade of radioiodine uptake, a common form of radiation poisoning due to environmental contamination by the short-lived fission product 131
. Potassium iodide may also be administered pharmaceutically for thyroid storm.
For reasons noted above, therapeutic drops of SSKI, or 130 mg tablets of KI as used for nuclear fission accidents, are not used as nutritional supplements, since an SSKI drop or nuclear-emergency tablet provides 300 to 700 times more iodine than the daily adult nutritional requirement. Dedicated nutritional iodide tablets containing 0.15 mg (150 micrograms (μg)) of iodide, from KI or from various other sources (such as kelp extract) are marketed as supplements, but they are not to be confused with the much higher pharmaceutical dose preparations.
Potassium iodide can be conveniently prepared in a saturated solution, abbreviated SSKI. This method of delivering potassium iodide doesn't require a method to weigh out the potassium iodide, thus allowing it to be used in an emergency situation. KI crystals are simply added to water until no more KI will dissolve and instead sits at the bottom of the container. With pure water, the concentration of KI in the solution depends only on the temperature. Potassium iodide is highly soluble in water thus SSKI is a concentrated source of KI. At 20 degrees Celsius the solubility of KI is 140-148 grams per 100 grams of water. Because the volumes of KI and water are approximately additive, the resulting SSKI solution will contain about 1.00 gram (1000 mg) KI per milliliter (mL) of solution. This is 100% weight/volume (note units of mass concentration) of KI (one gram KI per mL solution), which is possible because SSKI is significantly more dense than pure water—about 1.67 g/mL. Because KI is about 76.4% iodide by weight, SSKI contains about 764 mg iodide per mL. This concentration of iodide allows the calculation of the iodide dose per drop, if one knows the number of drops per milliliter. For SSKI, a solution more viscous than water, there are assumed to be 15 drops per mL; the iodide dose is therefore approximately 51 mg per drop. It is conventionally rounded to 50 mg per drop.
The term SSKI is also used, especially by pharmacists, to refer to a U.S.P. pre-prepared solution formula, made by adding KI to water to prepare a solution containing 1000 mg KI per mL solution (100% wt/volume KI solution), to closely approximate the concentration of SSKI made by saturation. This is essentially interchangeable with SSKI made by saturation, and also contains about 50 mg iodide per drop.
- Saturated solutions of potassium iodide can be an emergency treatment for hyperthyroidism (so-called thyroid storm), as high amounts of iodide temporarily suppress secretion of thyroxine from the thyroid gland. The dose typically begins with a loading dose, then 1⁄3 mL SSKI (5 drops or 250 mg iodine as iodide), three times per day.
- Iodide solutions made from a few drops of SSKI added to drinks have also been used as expectorants to increase the water content of respiratory secretions and encourage effective coughing.
- SSKI has been proposed as a topical treatment for sporotrichosis, but no trials have been conducted to determine the efficacy or side effects of such treatment.
- Potassium iodide has been used for symptomatic treatment of erythema nodosum patients for persistent lesions whose cause remains unknown. It has been used in cases of erythema nodosum associated with Crohn's disease.
- Due to its high potassium content, SSKI is extremely bitter, and if possible it is administered in a sugar cube or small ball of bread. It may also be mixed into much larger volumes of juices.
- Neither SSKI or KI tablets form nutritional supplements, since the nutritional requirement for iodine is only 150 micrograms (0.15 mg) of iodide per day. Thus, a drop of SSKI provides 50/0.15 = 333 times the daily iodine requirement, and a standard KI tablet provides twice this much.
- "Density of Potassium iodide". Aqua-Calc.
- "Potassium Iodide" (PDF). Retrieved 10 May 2019.
- National Research Council, Division on Earth and Life Studies; Board on Radiation Effects Research; Committee to Assess the Distribution and Administration of Potassium Iodide in the Event of a Nuclear Incident (2004). Distribution and Administration of Potassium Iodide in the Event of a Nuclear Incident. National Academies Press. p. 10. ISBN 978-0-309-09098-8. Archived from the original on 18 September 2017.
- Stwertka A (2002). A Guide to the Elements. Oxford University Press, USA. p. 137. ISBN 978-0-19-515026-1. Archived from the original on 14 September 2017.
- "Potassium Iodide". The American Society of Health-System Pharmacists. Archived from the original on 16 January 2017. Retrieved 8 January 2017.
- World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 390. hdl:10665/44053. ISBN 978-9-241-54765-9.
- Ensminger ME, Ensminger AH (1993). Foods & Nutrition Encyclopedia, Two Volume Set (s ed.). CRC Press. p. 16. ISBN 9780849389801. Archived from the original on 13 August 2017.
- Kaiho T (2014). Iodine Chemistry and Applications. John Wiley & Sons. p. 57. ISBN 978-1-118-87865-1. Archived from the original on 13 August 2017.
- Center for Drug Evaluation and Research (December 2001). "Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies". U.S. Food and Drug Administration.
- Oriel JD (2012). The Scars of Venus: A History of Venereology. Springer Science & Business Media. p. 87. ISBN 978-1-4471-2068-1. Archived from the original on 14 September 2017.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 224. ISBN 978-1-284-05756-0.
- Waszkowiak K, Szymandera-Buszka K (2008). "Effect of storage conditions on potassium iodide stability in iodised table salt and collagen preparations". International Journal of Food Science & Technology. 43 (5): 895–9. doi:10.1111/j.1365-2621.2007.01538.x.
- "Iodized Salt". Salt Institute. 13 July 2013. Archived from the original on 16 October 2013. Retrieved 13 June 2013.
- Kowalsky RJ, Falen, SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. 2nd ed. Washington DC: American Pharmacists Association; 2004.[page needed]
- Olivier P, Colarinha P, Fettich J, Fischer S, Frökier J, Giammarile F, et al. (May 2003). "Guidelines for radioiodinated MIBG scintigraphy in children" (PDF). European Journal of Nuclear Medicine and Molecular Imaging. 30 (5): B45–B50. doi:10.1007/s00259-003-1138-9. PMID 12658506. S2CID 20350450. Archived from the original (PDF) on 1 July 2007.
- "Highlight of Prescribing Information: AdreView Iobenguane I 123 Injection" (PDF). GE Healthcare. September 2008. Archived from the original (PDF) on 23 August 2011. Retrieved 23 March 2011.
- "Report on the Accident at the Chernobyl Nuclear Power Station, NUREG-1250". US Nuclear Regulatory Commission. Archived from the original on 8 July 2012. Retrieved 22 May 2012.
- Iobenguane Sulfate I 131 Injection Diagnostic package insert. Bedford, MA: CIS-US, Inc. July 1999.
- Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy" (PDF). European Journal of Nuclear Medicine and Molecular Imaging. 35 (5): 1039–1047. doi:10.1007/s00259-008-0715-3. PMID 18274745. S2CID 6884201. Archived from the original (PDF) on 7 October 2011.
- "Guidelines for Iodine Prophylaxis following Nuclear Accidents" (PDF). World Health Organization. 1999. Archived (PDF) from the original on 13 August 2013.
- Zanzonico PB, Becker DV (June 2000). "Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout". Health Physics. 78 (6): 660–667. doi:10.1097/00004032-200006000-00008. PMID 10832925. S2CID 30989865.
- "FAQs: Japan nuclear concerns". World Health Organization. Archived from the original on 1 April 2011. Retrieved 1 April 2011.
- By 21 CFR 184.1634, the maximum allowable concentration of iodine in salt in the U.S. is .01%
- "Safety (MSDS) data for sodium chloride". Archived from the original on 30 October 2007. Retrieved 2 April 2011.
- "Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies" (PDF). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2001. Archived (PDF) from the original on 15 April 2017.
- "Facts about patassium-iodine". U.S. Centers for Disease Control and Prevention. 10 November 2022.
- McCance; Huether. "Pathophysiology: The biological basis for disease in Adults and Children". 5th Edition. Elsievier Publishing[page needed]
- "POTASSIUM IODIDE - ORAL (SSKI) side effects, medical uses, and drug interactions". Medicinenet.com. Archived from the original on 24 March 2011. Retrieved 23 March 2011.
- Chmyrov A, Sandén T, Widengren J (September 2010). "Iodide as a fluorescence quencher and promoter--mechanisms and possible implications". The Journal of Physical Chemistry. B. 114 (34): 11282–11291. doi:10.1021/jp103837f. PMID 20695476.
- Lyday PA, Kaiho T (June 2000). "Iodine and Iodine Compounds.". Ullmann's Encyclopedia of Industrial Chemistry. Vol. 15. pp. 1–3. doi:10.1002/14356007.a14_381. ISBN 3527306730.
- Greenwood NN, Earnshaw A (1984). Chemistry of the Elements. Oxford, UK: Pergamon Press. ISBN 978-0-08-022057-4.[page needed]
- Handbook of Chemistry and Physics (71st ed.). Ann Arbor, Michigan: CRC Press. 1990. OCLC 1079892637.
- The Merck Index (7th ed.). Rahway, New Jersey: Merck & Co. 1960. OCLC 679352005.[page needed]
- Wade LG (2003). Organic chemistry (5th ed.). Upper Saddle River, N.J.: Prentice Hall. pp. 871–2. ISBN 978-0-13-033832-7.
- March J (1992). Advanced Organic Chemistry: Reactions, Mechanisms, and Structure (4th ed.). New York: Wiley. pp. 670–1. ISBN 978-0-471-58148-2.
- Nauman J, Wolff J (May 1993). "Iodide prophylaxis in Poland after the Chernobyl reactor accident: benefits and risks". The American Journal of Medicine (Submitted manuscript). 94 (5): 524–532. doi:10.1016/0002-9343(93)90089-8. PMID 8498398.
- Frot J. The Causes of the Chernobyl Event (doc) (Report). Berol Robinson (trans.). Environmentalists for Nuclear Energy. Archived from the original on 8 April 2012.
- "Guidance on Protection Against Thyroid Cancer in Case of a Nuclear Accident". FDA Talk Paper. US Food and Drug Administration. 3 December 2015.
- "Assessment of the Use of Potassium Iodide (KI) As a Public Protective Action During Severe Reactor Accidents Quoting Thyroid Cancer in Children of Belarus Following the Chernobyl Accident, NUREG-1633" (PDF). US Nuclear Regulatory Commission. Archived (PDF) from the original on 14 May 2009. Retrieved 22 May 2012.[page needed]
- Chernobyl, a Continuing Catastrophe (PDF). Office for the Coordination of Humanitarian Affairs (OCHA) (Report). New York and Geneva: United Nations. 2000. p. 5.
- Imaizumi M, Usa T, Tominaga T, Neriishi K, Akahoshi M, Nakashima E, et al. (March 2006). "Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure". JAMA. 295 (9): 1011–1022. doi:10.1001/jama.295.9.1011. PMID 16507802.
- Boice JD (March 2006). "Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl". JAMA. 295 (9): 1060–1062. doi:10.1001/jama.295.9.1060. PMID 16507808.
- "Federal Register". US Federal Register. 43 (242). 15 December 1978.
- "Vegetables near stricken plant test high for radiation". CNN. 22 March 2011. Archived from the original on 9 November 2012.
- De Limburger (11-March-2016) six questions about a half of million iodine pills
- Dutch Government radiation iodine tablets
- Get iodine tablets from the pharmacy, website created as part of the information campaign 'Do you know what to do in case of a nuclear accident?' in March–May 2018, implementing the EU Directive 89/618 Euratom and the nuclear and radiological emergency plan for the Belgian territory.
- McFee RB, Leikin JB (2008). Toxico-terrorism: emergency response and clinical approach to chemical, biological, and radiological agents. Vol. 755. New York: McGraw-Hill Medical. p. 224. ISBN 978-0-07-147186-2. Retrieved 18 December 2010.
- "Request for information:critical Foreign Dependencies". Wikileaks. February 2009. Archived from the original on 5 January 2016.
- "Potassium Iodide Dosage Guidelines & Frequently Asked Questions". Preparedness.com. 10 December 2001. Archived from the original on 17 March 2011. Retrieved 23 March 2011.
- "Solubility of KI in water". Hazard.com. 21 April 1998. Archived from the original on 23 April 2012. Retrieved 21 January 2013.
- Forster M, Flenley JR (1993). "Pollen purification and fractionation by equilibrium density gradient centrifugation". Palynology. 17: 137–55. doi:10.1080/01916122.1993.9989424. JSTOR 3687792.
- "Iodine". MedlinePlus. U.S. National Library of Medicine. Archived from the original on 4 August 2010.
- Saljoughian M (20 June 2011). "Potassium Iodide: An Antidote for Radiation Exposure". U.S. Pharmacist. Archived from the original on 5 February 2016. Retrieved 29 January 2016.
- Xue S, Gu R, Wu T, Zhang M, Wang X (October 2009). Wu T (ed.). "Oral potassium iodide for the treatment of sporotrichosis". The Cochrane Database of Systematic Reviews. 2009 (4): CD006136. doi:10.1002/14651858.CD006136.pub2. PMC 7388325. PMID 19821356.
- Marshall JK, Irvine EJ (September 1997). "Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide". Canadian Journal of Gastroenterology = Journal Canadien de Gastroenterologie. 11 (6): 501–502. doi:10.1155/1997/434989. PMID 9347164.
- "Potassium iodide". Drug Information Portal. U.S. National Library of Medicine.
- World Health Organization's guidelines for iodine prophylaxis following a nuclear accident